Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S P Seitz

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 27, 2001
Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenzJ A Markwalder, D D Christ, A Mutlib, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenzA E Mutlib, H Chen, G A Nemeth, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residuesM Patel, L T Bacheler, M M Rayner, et al.
Journal of Medicinal Chemistry|April 20, 2001
Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitorsD A Nugiel, A M Etzkorn, A Vidwans, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 1999
Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitorsM Patel, S S Ko, R J McHugh, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitorsM Patel, R F Kaltenbach, D A Nugiel, et al.
Journal of Medicinal Chemistry|May 24, 1996
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitorsD A Nugiel, K Jacobs, R F Kaltenbach, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2001
Quinazolines as cyclin dependent kinase inhibitorsT M Sielecki, T L Johnson, J Liu, et al.
Toxicology and Applied Pharmacology|November 15, 2000
The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in ratsA E Mutlib, R J Gerson, P C Meunier, et al.
Journal of Medicinal Chemistry|May 9, 1997
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysisD A Nugiel, K Jacobs, L Cornelius, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|March 27, 2001
Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenzJ A Markwalder, D D Christ, A Mutlib, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenzA E Mutlib, H Chen, G A Nemeth, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residuesM Patel, L T Bacheler, M M Rayner, et al.
Journal of Medicinal Chemistry|April 20, 2001
Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitorsD A Nugiel, A M Etzkorn, A Vidwans, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 1999
Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitorsM Patel, S S Ko, R J McHugh, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitorsM Patel, R F Kaltenbach, D A Nugiel, et al.
Journal of Medicinal Chemistry|May 24, 1996
Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitorsD A Nugiel, K Jacobs, R F Kaltenbach, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2001
Quinazolines as cyclin dependent kinase inhibitorsT M Sielecki, T L Johnson, J Liu, et al.
Toxicology and Applied Pharmacology|November 15, 2000
The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in ratsA E Mutlib, R J Gerson, P C Meunier, et al.
Journal of Medicinal Chemistry|May 9, 1997
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysisD A Nugiel, K Jacobs, L Cornelius, et al.
Pageof 3